Author | George R. Blumenshein, MD


Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

December 03, 2000

ByRitsuko Komaki, MD|Nora A. Janjan, MD|Jaffer A. Ajani, MD|Patrick M. Lynch, MD|Jackie S. Fairweather, RN|Isaac Raijman, MD|George R. Blumenshein, MD|Linus Ho, MD, PhD|Peter W. T. Pisters, MD|Barry W. Feig, MD|Garrett L. Walsh, MD|Richard Pazdur, MD

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly